NO20024763L - Kinazolinforbindelser - Google Patents

Kinazolinforbindelser

Info

Publication number: NO20024763L
Authority: NO; Norway
Prior art keywords: sup; aromatic; ring; saturated; psorlasis
Prior art date: 2000-04-07

Application number

NO20024763A

Other languages

English (en)

Other versions

NO324471B1 (no

NO20024763D0 (no

Inventor

Laurent Francois And Hennequin

Elaine Sophie Elizabeth Stokes

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-07

Filing date

2002-10-03

Publication date

2002-11-19

2002-10-03 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2002-10-03 Publication of NO20024763D0 publication Critical patent/NO20024763D0/no

2002-11-19 Publication of NO20024763L publication Critical patent/NO20024763L/no

2007-10-29 Publication of NO324471B1 publication Critical patent/NO324471B1/no

Links

JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
125000003118 aryl group Chemical group 0.000 abstract 2
229920006395 saturated elastomer Polymers 0.000 abstract 2
125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
230000001772 anti-angiogenic effect Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
230000001603 reducing effect Effects 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
230000008728 vascular permeability Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Gynecology & Obstetrics (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Surgery (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pregnancy & Childbirth (AREA)
Transplantation (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20024763A 2000-04-07 2002-10-03 Kinazolinforbindelser samt anvendelse og fremgangsmate for fremstilling derav og farmasoytisk sammensetning NO324471B1 (no)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP00400967		2000-04-07
EP00400968		2000-04-07
EP00401034		2000-04-13
EP00401033		2000-04-13
PCT/GB2001/001514 WO2001077085A1 (en)	2000-04-07	2001-04-03	Quinazoline compounds

Publications (3)

Publication Number	Publication Date
NO20024763D0 NO20024763D0 (no)	2002-10-03
NO20024763L true NO20024763L (no)	2002-11-19
NO324471B1 NO324471B1 (no)	2007-10-29

Family

ID=27440054

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20024763A NO324471B1 (no)	2000-04-07	2002-10-03	Kinazolinforbindelser samt anvendelse og fremgangsmate for fremstilling derav og farmasoytisk sammensetning

Country Status (20)

Country	Link
US (2)	US7160889B2 (no)
EP (1)	EP1274692B1 (no)
JP (2)	JP4970689B2 (no)
KR (1)	KR100858069B1 (no)
CN (1)	CN1240688C (no)
AT (1)	ATE334973T1 (no)
AU (1)	AU779695B2 (no)
BR (1)	BR0109828A (no)
CA (1)	CA2403365A1 (no)
CY (1)	CY1107539T1 (no)
DE (1)	DE60121931T2 (no)
DK (1)	DK1274692T3 (no)
ES (1)	ES2267748T3 (no)
IL (2)	IL151626A0 (no)
MX (1)	MXPA02009891A (no)
NO (1)	NO324471B1 (no)
NZ (1)	NZ521421A (no)
PT (1)	PT1274692E (no)
SI (1)	SI1274692T1 (no)
WO (1)	WO2001077085A1 (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HK1044769B (zh) *	1999-06-21	2005-02-25	贝林格尔英格海姆法玛两合公司	雙環雜環化合物，含有該化合物的藥物組合物，該化合物的用途及其製備方法
KR100881105B1 (ko) *	1999-11-05	2009-02-02	아스트라제네카 아베	Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
AU2001235804A1 (en)	2000-03-06	2001-09-17	Astrazeneca Ab	Therapy
UA73993C2 (uk)	2000-06-06	2005-10-17	Астразенека Аб	Хіназолінові похідні для лікування пухлин та фармацевтична композиція
WO2002016352A1 (en)	2000-08-21	2002-02-28	Astrazeneca Ab	Quinazoline derivatives
JP2004511479A (ja)	2000-10-13	2004-04-15	アストラゼネカ　アクチボラグ	キナゾリン誘導体
AU2001292137A1 (en)	2000-10-13	2002-04-22	Astrazeneca Ab	Quinazoline derivatives
JP4564713B2 (ja)	2000-11-01	2010-10-20	ミレニアム・ファーマシューティカルズ・インコーポレイテッド	窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
US7019012B2 (en)	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
JP4307843B2 (ja)	2001-04-19	2009-08-05	アストラゼネカアクチボラグ	キナゾリン誘導体
SI1474420T1 (sl)	2002-02-01	2012-06-29	Astrazeneca Ab	Spojine kinazolina
US6924285B2 (en)	2002-03-30	2005-08-02	Boehringer Ingelheim Pharma Gmbh & Co.	Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE10221018A1 (de) *	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US7576074B2 (en)	2002-07-15	2009-08-18	Rice Kenneth D	Receptor-type kinase modulators and methods of use
AU2003278383B2 (en)	2002-11-04	2007-06-14	Astrazeneca Ab	Quinazoline derivatives as Src tyrosine kinase inhibitors
AU2003292435A1 (en) *	2002-12-23	2004-07-14	Astrazeneca Ab	4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
US7223749B2 (en) *	2003-02-20	2007-05-29	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE10326186A1 (de) *	2003-06-06	2004-12-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
GB0317665D0 (en)	2003-07-29	2003-09-03	Astrazeneca Ab	Qinazoline derivatives
GB0318423D0 (en) *	2003-08-06	2003-09-10	Astrazeneca Ab	Chemical compounds
ATE395346T1 (de)	2003-09-16	2008-05-15	Astrazeneca Ab	Chinazolinderivate als tyrosinkinaseinhibitoren
GB0322409D0 (en)	2003-09-25	2003-10-29	Astrazeneca Ab	Quinazoline derivatives
US7456189B2 (en)	2003-09-30	2008-11-25	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
GB0326459D0 (en)	2003-11-13	2003-12-17	Astrazeneca Ab	Quinazoline derivatives
WO2005061470A1 (en) *	2003-12-18	2005-07-07	Cv Therapeutics, Inc.	1-akan-2-ol substituted piperazine and piperidine compounds
EP2650286A1 (en) *	2004-02-19	2013-10-16	Rexahn Pharmaceuticals, Inc.	Quinazoline derivatives and therapeutic use thereof
US7687502B2 (en) *	2004-03-23	2010-03-30	Banyu Pharmaceutical Co., Ltd.	Substituted quinazoline or pyridopyrimidine derivative
KR20080095915A (ko)	2004-05-06	2008-10-29	워너-램버트 캄파니 엘엘씨	4-페닐아미노-퀴나졸린-6-일-아미드
AR050948A1 (es)	2004-09-24	2006-12-06	Hoffmann La Roche	Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
US7285569B2 (en)	2004-09-24	2007-10-23	Hoff Hoffmann-La Roche Inc.	Tricycles, their manufacture and use as pharmaceutical agents
KR20070113286A (ko)	2005-04-14	2007-11-28	에프. 호프만-라 로슈 아게	아미노피라졸 유도체, 이의 제조 및 약학 제제로서의 용도
WO2007033196A1 (en)	2005-09-14	2007-03-22	Bristol-Myers Squibb Company	Met kinase inhibitors
JP5688877B2 (ja)	2005-11-11	2015-03-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	癌疾患の治療用キナゾリン誘導体
AU2007299080B2 (en) *	2006-09-18	2013-04-18	Boehringer Ingelheim International Gmbh	Method for treating cancer harboring EGFR mutations
EP1921070A1 (de)	2006-11-10	2008-05-14	Boehringer Ingelheim Pharma GmbH & Co. KG	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
AU2008212999A1 (en)	2007-02-06	2008-08-14	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
US20080190689A1 (en) *	2007-02-12	2008-08-14	Ballard Ebbin C	Inserts for engine exhaust systems
US8497369B2 (en)	2008-02-07	2013-07-30	Boehringer Ingelheim International Gmbh	Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
JP5739802B2 (ja)	2008-05-13	2015-06-24	アストラゼネカアクチボラグ	４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
EP2313397B1 (de)	2008-08-08	2016-04-20	Boehringer Ingelheim International GmbH	Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
PT2451445T (pt)	2009-07-06	2019-07-10	Boehringer Ingelheim Int	Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo
CN102060875B (zh) *	2009-11-18	2014-03-12	天津药物研究院	喹唑啉衍生物、制备方法和用途
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN105153047A (zh) *	2015-08-25	2015-12-16	佛山市赛维斯医药科技有限公司	含新型苯并喹唑啉和邻位氟结构的酪氨酸激酶抑制剂及用途
JP6740354B2 (ja)	2015-10-05	2020-08-12	ザトラスティーズオブコロンビアユニバーシティーインザシティーオブニューヨーク	オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
CN106083836B (zh) *	2016-06-26	2021-08-20	徐州医学院	基于喹唑啉结构的h2s供体化合物及其应用

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE317376B (no) *	1961-07-10	1969-11-17	Roussel Uclaf
US3266990A (en) *	1963-09-24	1966-08-16	Warner Lambert Pharmaceutical	Derivatives of quinazoline
FR2077455A1 (en)	1969-09-03	1971-10-29	Aries Robert	5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials
US3870725A (en)	1971-03-30	1975-03-11	Lilly Industries Ltd	Nitrothiazole derivatives
JPS542327A (en)	1977-06-07	1979-01-09	Sankyo Co Ltd	Agricultural and horticultural pesticide
JPS5538325A (en)	1978-09-11	1980-03-17	Sankyo Co Ltd	4-anilinoquinazoline derivative and its preparation
US4343940A (en) *	1979-02-13	1982-08-10	Mead Johnson & Company	Anti-tumor quinazoline compounds
FR2498187A1 (fr) *	1981-01-16	1982-07-23	Rhone Poulenc Sante	Procede de preparation d'amino-4 chloro-7 quinoleines
GB2160201B (en)	1984-06-14	1988-05-11	Wyeth John & Brother Ltd	Quinazoline and cinnoline derivatives
IL81307A0 (en)	1986-01-23	1987-08-31	Union Carbide Agricult	Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
EP0326307B1 (en)	1988-01-23	1994-08-17	Kyowa Hakko Kogyo Co., Ltd.	Novel pyridazinone derivatives and pharmaceutical preparations containing them
US5411963A (en) *	1988-01-29	1995-05-02	Dowelanco	Quinazoline derivatives
IL89029A (en)	1988-01-29	1993-01-31	Lilly Co Eli	Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
HUT64755A (en)	1991-02-20	1994-02-28	Pfizer	Process for the production of 2,4-diamino-quinazoline derivatives and of medical preparatives containing them
IL101291A0 (en)	1991-03-22	1992-11-15	Nippon Soda Co	2-pyridine derivatives,their preparation and their use as fungicides
US5480883A (en) *	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) *	1991-05-10	1998-02-24	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5714493A (en) *	1991-05-10	1998-02-03	Rhone-Poulenc Rorer Pharmaceuticals, Inc.	Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en)	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
SG64322A1 (en)	1991-05-10	1999-04-27	Rhone Poulenc Rorer Int	Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en)	1991-06-28	1995-02-24	Ici Plc	4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
CA2114727C (en)	1991-08-02	1996-12-10	Mikel P. Moyer	Quinoline derivatives as immunostimulants
GB9127252D0 (en)	1991-12-23	1992-02-19	Boots Co Plc	Therapeutic agents
GB9300059D0 (en) *	1992-01-20	1993-03-03	Zeneca Ltd	Quinazoline derivatives
DE4208254A1 (de) *	1992-03-14	1993-09-16	Hoechst Ag	Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
US5270466A (en) *	1992-06-11	1993-12-14	American Cyanamid Company	Substituted quinazoline fungicidal agents
JP2994165B2 (ja) *	1992-06-26	1999-12-27	ゼネカ・リミテッド	キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
US5712395A (en) *	1992-11-13	1998-01-27	Yissum Research Development Corp.	Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) *	1992-11-13	1998-08-11	Sugen, Inc.	Quinazoline compounds and compositions thereof for the treatment of disease
US6177401B1 (en)	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en)	1992-12-10	1994-01-05	Zeneca Ltd	Quinazoline derivatives
GB9314893D0 (en) *	1993-07-19	1993-09-01	Zeneca Ltd	Quinazoline derivatives
GB9314884D0 (en)	1993-07-19	1993-09-01	Zeneca Ltd	Tricyclic derivatives
US5656643A (en) *	1993-11-08	1997-08-12	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5700823A (en)	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers
RU2137762C1 (ru)	1994-02-23	1999-09-20	Пфайзер Инк.	4-гетероциклил-замещенные производные хиназолина, фармацевтическая композиция
WO1995024190A2 (en)	1994-03-07	1995-09-14	Sugen, Inc.	Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
TW321649B (no)	1994-11-12	1997-12-01	Zeneca Ltd
GB9424233D0 (en) *	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
AU5108196A (en)	1995-03-20	1996-10-08	Dr. Karl Thomae Gmbh	Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation
IL117620A0 (en)	1995-03-27	1996-07-23	Fujisawa Pharmaceutical Co	Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
DE69536015D1 (de)	1995-03-30	2009-12-10	Pfizer Prod Inc	Chinazolinone Derivate
GB9508537D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9508535D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivative
GB9508565D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quiazoline derivative
JPH11507329A (ja)	1995-04-27	1999-06-29	ゼネカリミテッド	キナゾリン誘導体
TW334434B (en)	1995-05-16	1998-06-21	Kanebo Ltd	Novel quinazoline compound and anti-tumor agent
US5747498A (en) *	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
CA2222545A1 (en)	1995-06-07	1996-12-19	Sugen, Inc.	Quinazolines and pharmaceutical compositions
US5773459A (en)	1995-06-07	1998-06-30	Sugen, Inc.	Urea- and thiourea-type compounds
US5650415A (en) *	1995-06-07	1997-07-22	Sugen, Inc.	Quinoline compounds
SI9620103A (sl)	1995-07-06	1998-10-31	Novartis Ag	Pirolopirimidini in postopki za njihovo pripravo
GB9514265D0 (en)	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
EP0860433B1 (en)	1995-11-07	2002-07-03	Kirin Beer Kabushiki Kaisha	Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
GB9624482D0 (en) *	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
CH690773A5 (de)	1996-02-01	2001-01-15	Novartis Ag	Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
US5760041A (en)	1996-02-05	1998-06-02	American Cyanamid Company	4-aminoquinazoline EGFR Inhibitors
DE69720965T2 (de) *	1996-02-13	2004-02-05	Astrazeneca Ab	Chinazolinderivate und deren verwendung als vegf hemmer
GB9603097D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline compounds
GB9603095D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
NZ331191A (en) *	1996-03-05	2000-03-27	Zeneca Ltd	4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
AU2103097A (en) *	1996-03-15	1997-10-10	Zeneca Limited	Cinnoline derivatives and use as medicine
WO1997037999A1 (en)	1996-04-04	1997-10-16	University Of Nebraska Board Of Regents	Synthetic triple helix-forming compounds
EA001595B1 (ru) *	1996-04-12	2001-06-25	Варнер-Ламберт Компани	Необратимые ингибиторы тирозинкиназ
GB9607729D0 (en) *	1996-04-13	1996-06-19	Zeneca Ltd	Quinazoline derivatives
DE19614718A1 (de)	1996-04-15	1997-10-16	Hoechst Schering Agrevo Gmbh	Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel
GB9707800D0 (en)	1996-05-06	1997-06-04	Zeneca Ltd	Chemical compounds
GB9613021D0 (en)	1996-06-21	1996-08-28	Pharmacia Spa	Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
AR007857A1 (es)	1996-07-13	1999-11-24	Glaxo Group Ltd	Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
EP0954315A2 (en)	1996-09-13	1999-11-10	Sugen, Inc.	Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
GB9718972D0 (en) *	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
WO1998013350A1 (en)	1996-09-25	1998-04-02	Zeneca Limited	Qinoline derivatives inhibiting the effect of growth factors such as vegf
EP0882717B1 (en)	1996-10-01	2010-09-08	Kyowa Hakko Kirin Co., Ltd.	Nitrogenous heterocyclic compounds
EP0837063A1 (en)	1996-10-17	1998-04-22	Pfizer Inc.	4-Aminoquinazoline derivatives
WO1998023613A1 (en)	1996-11-27	1998-06-04	Pfizer Inc.	Fused bicyclic pyrimidine derivatives
CO4950519A1 (es)	1997-02-13	2000-09-01	Novartis Ag	Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6002008A (en) *	1997-04-03	1999-12-14	American Cyanamid Company	Substituted 3-cyano quinolines
UA73073C2 (uk)	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US5929080A (en) *	1997-05-06	1999-07-27	American Cyanamid Company	Method of treating polycystic kidney disease
WO1998050038A1 (en)	1997-05-06	1998-11-12	American Cyanamid Company	Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986729B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitors of tyrosine kinases
ZA986732B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
TW436485B (en)	1997-08-01	2001-05-28	American Cyanamid Co	Substituted quinazoline derivatives
AR016817A1 (es)	1997-08-14	2001-08-01	Smithkline Beecham Plc	Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
ES2289791T3 (es)	1997-08-22	2008-02-01	Astrazeneca Ab	Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
US7262201B1 (en)	1998-10-08	2007-08-28	Astrazeneca Ab	Quinazoline derivatives
PT1154774E (pt)	1999-02-10	2005-10-31	Astrazeneca Ab	Derivados de quinazolina como inibidores de angiogenese
DE19911509A1 (de)	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
KR100881105B1 (ko)	1999-11-05	2009-02-02	아스트라제네카 아베	Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
AU2001235804A1 (en) *	2000-03-06	2001-09-17	Astrazeneca Ab	Therapy
GB0008269D0 (en)	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
WO2002012226A1 (en) *	2000-08-09	2002-02-14	Astrazeneca Ab	Quinoline derivatives having vegf inhibiting activity
WO2002012227A2 (en)	2000-08-09	2002-02-14	Astrazeneca Ab	Indole, azaindole and indazole derivatives having vegf inhibiting activity
WO2002012228A1 (en)	2000-08-09	2002-02-14	Astrazeneca Ab	Cinnoline compounds
GB0126879D0 (en)	2001-11-08	2002-01-02	Astrazeneca Ab	Combination therapy
SI1474420T1 (sl)	2002-02-01	2012-06-29	Astrazeneca Ab	Spojine kinazolina
AU2003249000B2 (en)	2002-08-09	2007-04-05	Astrazeneca Ab	Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en)	2002-08-09	2002-09-18	Astrazeneca Ab	Combination therapy
GB0223380D0 (en)	2002-10-09	2002-11-13	Astrazeneca Ab	Combination therapy
KR20050100683A (ko)	2003-02-13	2005-10-19	아스트라제네카 아베	5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법

2001
- 2001-04-03 ES ES01921530T patent/ES2267748T3/es not_active Expired - Lifetime
- 2001-04-03 PT PT01921530T patent/PT1274692E/pt unknown
- 2001-04-03 DK DK01921530T patent/DK1274692T3/da active
- 2001-04-03 AU AU48507/01A patent/AU779695B2/en not_active Ceased
- 2001-04-03 CA CA002403365A patent/CA2403365A1/en not_active Abandoned
- 2001-04-03 WO PCT/GB2001/001514 patent/WO2001077085A1/en not_active Ceased
- 2001-04-03 KR KR1020027013364A patent/KR100858069B1/ko not_active Expired - Fee Related
- 2001-04-03 BR BR0109828-4A patent/BR0109828A/pt not_active IP Right Cessation
- 2001-04-03 NZ NZ521421A patent/NZ521421A/en unknown
- 2001-04-03 DE DE60121931T patent/DE60121931T2/de not_active Expired - Lifetime
- 2001-04-03 US US10/240,658 patent/US7160889B2/en not_active Expired - Fee Related
- 2001-04-03 SI SI200130631T patent/SI1274692T1/sl unknown
- 2001-04-03 EP EP01921530A patent/EP1274692B1/en not_active Expired - Lifetime
- 2001-04-03 AT AT01921530T patent/ATE334973T1/de not_active IP Right Cessation
- 2001-04-03 IL IL15162601A patent/IL151626A0/xx active IP Right Grant
- 2001-04-03 JP JP2001575560A patent/JP4970689B2/ja not_active Expired - Fee Related
- 2001-04-03 CN CNB018106846A patent/CN1240688C/zh not_active Expired - Fee Related
- 2001-04-03 MX MXPA02009891A patent/MXPA02009891A/es active IP Right Grant
2002
- 2002-09-05 IL IL151626A patent/IL151626A/en not_active IP Right Cessation
- 2002-10-03 NO NO20024763A patent/NO324471B1/no not_active IP Right Cessation
2006
- 2006-11-01 CY CY20061101562T patent/CY1107539T1/el unknown
- 2006-11-17 US US11/600,752 patent/US20070066633A1/en not_active Abandoned
2012
- 2012-02-23 JP JP2012037026A patent/JP2012136537A/ja active Pending

Also Published As

Publication number	Publication date
ATE334973T1 (de)	2006-08-15
BR0109828A (pt)	2002-12-17
NZ521421A (en)	2004-09-24
IL151626A (en)	2008-06-05
CA2403365A1 (en)	2001-10-18
US20070066633A1 (en)	2007-03-22
JP2012136537A (ja)	2012-07-19
EP1274692A1 (en)	2003-01-15
ES2267748T3 (es)	2007-03-16
NO324471B1 (no)	2007-10-29
DE60121931T2 (de)	2007-03-01
SI1274692T1 (sl)	2006-12-31
CY1107539T1 (el)	2013-03-13
KR20020084295A (ko)	2002-11-04
PT1274692E (pt)	2006-11-30
AU779695B2 (en)	2005-02-10
JP2003530387A (ja)	2003-10-14
EP1274692B1 (en)	2006-08-02
CN1240688C (zh)	2006-02-08
US20030191308A1 (en)	2003-10-09
NO20024763D0 (no)	2002-10-03
US7160889B2 (en)	2007-01-09
AU4850701A (en)	2001-10-23
KR100858069B1 (ko)	2008-09-22
WO2001077085A1 (en)	2001-10-18
DE60121931D1 (de)	2006-09-14
IL151626A0 (en)	2003-04-10
JP4970689B2 (ja)	2012-07-11
MXPA02009891A (es)	2003-03-27
DK1274692T3 (da)	2006-10-30
CN1433405A (zh)	2003-07-30

Legal Events

Date	Code	Title	Description
2010-11-29	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
DE60121931D1 (de)	2006-09-14	Chinazolinverbindungen
FI913478A0 (fi)	1991-07-18	Diazinderivat.
DE60322267D1 (de)	2008-08-28	Chinolinderivate als glucokinase liganden
ATE296826T1 (de)	2005-06-15	Pyrazolo(1,5)pyridinderivate
IS6658A (is)	2002-12-17	Ný efnasambönd
DK0790986T3 (da)	1999-09-13	Anilinderivater
IS6647A (is)	2002-12-02	Kínasólínafleiður til að meðhöndla æxli
DE69918422D1 (de)	2004-08-05	Phthalazinone pde iii/iv hemmer
ATE316083T1 (de)	2006-02-15	Adamantanderivate
NO20023933D0 (no)	2002-08-19	Nye forbindelser
ES2243579T3 (es)	2005-12-01	Derivados de pirazolopirideno.
BG103399A (en)	2000-01-31	New heterocycle-substituted benzamides and their application for the treatment of diseases
BR0209149A (pt)	2004-07-13	Ftalazinonas
DE60215178D1 (de)	2006-11-16	Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
DE60229046D1 (de)	2008-11-06	Chinazolin derivate
ATE311389T1 (de)	2005-12-15	Wirkstoffvorläufer von imidazopyridin-derivaten
SE0003476D0 (sv)	2000-09-28	Compounds
DE60108626D1 (de)	2005-03-03	Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
DE60131968D1 (de)	2008-01-31	PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
ES2104174T3 (es)	1997-10-01	Derivados de bencilamino, bencilamido y bencilimido ciclicos utilizados como agentes antipsicoticos.
ATE274513T1 (de)	2004-09-15	Verbindungen und verfahren zur behandlung von schmerz
CY1106472T1 (el)	2012-01-25	Η χρηση των παραγωγων υδροξυπυριδονης στην επουλωση πληγων
DE60305520D1 (de)	2006-06-29	2" oxo-voruscharin und derivaten